2026 Step Therapy Prior Authorization Medical Necessity Guidelines
Customize your policy alerts
Sign up for all harvard pilgrim health care policy alerts
Know when harvard pilgrim health care releases new policies or updates existing guidance.
Monitor payer policy activity
Step therapy prior authorization rules for specified drug products (antidepressants, atypical antipsychotics, inhaled corticosteroids, interferons) for Harvard Pilgrim Health Care members; outlines required prior medication fills or documentation to bypass authorization.
No material clinical or coverage changes in this revision.
Coverage Criteria by Therapeutic Category
Antidepressants
Antidepressants - Covered when conditions below are met
source: chunk 4
source: chunk 4
Atypical Antipsychotics
Atypical antipsychotics - Covered when conditions below are met
source: chunk 7
source: chunk 7
Inhaled Corticosteroids
Inhaled corticosteroids - Covered when conditions below are met
source: chunk 10
source: chunk 10
Interferons
Interferons - Covered when conditions below are met
source: chunk 13
source: chunk 13
Coding and Look-back Period
Provider Actions, Documentation, and Prior Authorization Requirements
Step-2 prior authorization requirement
Certain listed Step-2 drugs require prior authorization unless the member has evidence of a qualifying prior fill or physician documentation within the 180-day look-back period. Providers must submit paid pharmacy claims or physician documentation showing the required prior medication trial to avoid prior authorization denial for Step-2 products.
- Look-back period: 180 days (evidence via paid claim or physician documentation).
Antidepressants step therapy — Step‑1 vs Step‑2
Step-1 antidepressants (bupropion formulations, citalopram, desvenlafaxine ER, duloxetine delayed‑release capsules, escitalopram, fluoxetine formulations, fluvoxamine, paroxetine, sertraline, venlafaxine and venlafaxine ER) are covered without prior authorization. Emsam, Fetzima (including Fetzima Titration Pack), and Exxua are Step-2 and require evidence of a paid claim or physician documentation showing a fill for a Step-1 or Step-2 antidepressant within the previous 180 days to be covered.
- Step-1 (no prior auth): bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine ER, duloxetine delayed‑release capsules, escitalopram, fluoxetine, fluoxetine delayed‑release, fluvoxamine, paroxetine, sertraline, venlafaxine, venlafaxine ER.
- Step-2 (require prior fill/documentation): Emsam, Fetzima, Exxua (includes Fetzima Titration Pack).
Atypical antipsychotics step therapy — Step‑1 vs Step‑2
Certain atypical antipsychotics listed as Step-1 (aripiprazole, lurasidone, olanzapine, olanzapine‑fluoxetine, quetiapine, risperidone, ziprasidone) are covered without authorization. Asenapine and Fanapt (including Fanapt Titration Pack A) are Step-2 and will be covered only if the member has filled one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days as evidenced by a paid claim or physician documentation.
- Step-1 (no prior auth): aripiprazole, lurasidone, olanzapine, olanzapine‑fluoxetine, quetiapine, risperidone, ziprasidone.
- Step-2 (require prior fill/documentation): asenapine, Fanapt (Fanapt Titration Pack A).
Inhaled corticosteroids step therapy — QVAR (Step‑1) and fluticasone (Step‑2)
QVAR is designated Step-1 and is covered without prior authorization. Fluticasone products (e.g., Fluticasone Propionate HFA/Diskus) are Step-2 and will be covered only if the member has filled one or more Step-1 inhaled corticosteroids within the previous 180 days as evidenced by a paid claim or physician documentation.
- Step-1 (no prior auth): QVAR.
- Step-2 (require prior fill/documentation): fluticasone products (Fluticasone Propionate HFA/Diskus).
Interferons step therapy — Step‑1 vs Step‑2 (two‑fill requirement)
Avonex, Betaseron, and Plegridy are Step-1 and covered without prior authorization. Rebif and Rebif Rebidose (including their titration packs) are Step-2 and will be covered only if the member has filled two or more Step-1 interferon medications within the previous 180 days as evidenced by paid pharmacy claims or physician documentation.
- Step-1 (no prior auth): Avonex, Betaseron, Plegridy.
- Step-2 (require two prior fills/documentation): Rebif, Rebif Rebidose, and their titration packs — requires evidence of two or more Step‑1 fills within 180 days.
Evidence of prior medication trials (documentation required)
Physician documentation or paid pharmacy claims must show the member filled the required Step-1 (or Step-2 where permitted) medications within the prior 180 days to support coverage of Step-2 products. Absence of this evidence may result in denial of coverage for Step-2 drugs.
- Acceptable evidence: paid pharmacy claim(s) within 180 days or physician documentation confirming the fill(s).
- Interferons specifically require two or more Step‑1 fills within 180 days for Step‑2 coverage.
Prior fill requirement for Step‑2 drugs (denial risk)
Coverage for Step-2 medications requires evidence of the required number of prior fills within the previous 180 days: one or more fills for most Step-2 drugs, but two or more fills for interferon Step-2 products; failure to provide this evidence may lead to denial.
- Antidepressants, atypical antipsychotics, and inhaled corticosteroids: evidence of one or more Step‑1 (or Step‑2 where allowed) fills within 180 days.
- Interferons: evidence of two or more Step‑1 fills within 180 days for Step‑2 coverage.
Step-Therapy Operational Rules and Member Fill Requirements
| Requirement | Coverage |
|---|---|
| Member must have filled for a Step-1 or Step-2 antidepressant within the previous 180 days (paid claim) or provide physician documentation | |
| Step-2 antidepressants (Emsam, Fetzima, Exxua, including titration packs) will be covered when the prior fill or documentation requirement is met |
| Requirement | Coverage |
|---|---|
| Member must have filled for one or more Step-1 or Step-2 atypical antipsychotics within the previous 180 days (paid claim) or provide physician documentation | |
| Step-2 atypical antipsychotics (asenapine, Fanapt, including Fanapt titration pack) will be covered when the prior fill or documentation requirement is met |
| Requirement | Coverage |
|---|---|
| Member must have filled for one or more Step-1 inhaled corticosteroids within the previous 180 days (paid claim) or provide physician documentation | |
| Step-2 inhaled corticosteroid products (fluticasone formulations) will be covered when the prior fill or documentation requirement is met |
| Requirement | Coverage |
|---|---|
| Member must have filled for two or more Step-1 interferon medications within the previous 180 days (paid claims) or provide physician documentation | |
| Step-2 interferons (Rebif, Rebif Rebidose, and titration packs) will be covered when the two-fill prior requirement or documentation is met |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.